Screening strategies for antenatal Down syndrome screening
OConnell R,Stephenson M,Weir R
Record ID 32007000113
English
Authors' objectives:
This review aimed to systematically appraise the international evidence for the use of technologies and screening strategies for antenatal Down syndrome. Including: The validity of Down syndrome screening methods Any difficulties implementing screening strategies The impact of screening on amniocentesis and chorionic villus sampling The safety of these procedures.
Authors' results and conclusions:
Accuracy of screening methods: Maternal age alone is not an appropriate screening test for DS.
Screening methods that combine tests in an independent manner are not recommended.
The quad test provided the best screening performance characteristics in the 2nd trimester
The combined test performed better than other 1st trimester tests and all 2nd trimester strategies, and serum integrated screening had a similar performance to the combined test.
All other integrated and sequential screening strategies have improved performance compared to either 1st trimester or 2nd trimester screening strategies.
Integrated screening performed better than both stepwise and contingent screening, with a lower FPR for a fixed DR.
The performance of stepwise and contingent screening is similar.
Authors' methods:
Systematic Review
Details
Project Status:
Completed
URL for project:
http://nzhta.chmeds.ac.nz/publications.htm
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
New Zealand
MeSH Terms
- Chromosomes, Human, Pair 21
- Pregnancy Trimester, First
- Pregnancy Trimester, Second
- Amniocentesis
- Chorionic Villi Sampling
- Down Syndrome
- Mass Screening
- Nuchal Translucency Measurement
- Prenatal Diagnosis
- Ultrasonography, Prenatal
Contact
Organisation Name:
New Zealand Health Technology Assessment
Contact Address:
Department of Public Health and General Practice, Christchurch School of Medicine and Health Sciences, University of Otago, P.O. Box 4345, Christchurch, New Zealand. Tel: +64 3 364 1145; Fax: +64 3 364 1152;
Contact Name:
nzhta@chmeds.ac.nz
Contact Email:
nzhta@chmeds.ac.nz
Copyright:
New Zealand Health Technology Assessment (NZHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.